
1. ther adv chronic dis. 2013 jan;4(1):45-51. doi: 10.1177/2040622312466279.

recent advances treating multiple sclerosis: efficacy, risks place in
therapy.

jeffery dr(1).

author information: 
(1)director ms center, advance neurology cornerstone health care, 152
kinderton way, suite 101, advance, nc 27006, usa.

the development new pharmacologic agents treatment multiple
sclerosis (ms) advances testing exposure jc virus led to
changes treatment ms. addition several new agents late stage 
development ms entry onto market provide additional
treatment options. 2012 early 2013, likely terifunomide
and bg-12 approved united states food drug administration
(fda) treatment relapsing forms ms. therapeutic environment has
already changed likely change rapidly next several years.
fingolimod first oral agent approved treatment ms this
agent widely used patients intolerant injections side
effects associated older platform therapies. many settings also
used first-line agent. owing risk progressive multifocal
leukoencephalopathy, natalizumab previously reserved patients with
active disease intolerant first-line agents patients were
worsening despite standard therapy. availability jc virus antibody
testing, natalizumab used first-line agent patients negative
for jc virus antibodies. teriflunomide bg-12 become available the
next year. agents suitable efficacy favorable safety and
tolerability profile. advantages disadvantages associated 
of oral agents. article summarize clinical trial results
regarding efficacy safety oral agents discuss changes that
are already taking place therapeutic landscape ms.

doi: 10.1177/2040622312466279 
pmcid: pmc3539264
pmid: 23342246 

